Alcon: agreement to acquire Aerie Pharmaceuticals
(CercleFinance.com) - On Monday evening Alcon announced that it has entered into a definitive merger agreement to acquire Aerie Pharmaceuticals, a pharmaceutical company focused on the discovery, development, manufacturing and marketing of leading ophthalmic therapies.
The transaction will bring Alcon's glaucoma products Rocklatan and Rhopressa, as well as AR-15512, a Phase 3 product candidate for dry eye, and other ophthalmic drug candidates in clinical and preclinical phases.
This transaction, which has an equity value of approximately 770 million dollars, is expected to be accretive to Alcon's EPS in 2024. It is expected to close in Q4 2022, subject to customary closing conditions.
Copyright (c) 2022 CercleFinance.com. All rights reserved.